Vicore Pharma Holding AB (publ) Cash Flow Conversion Efficiency

Latest as of December 2025: -0.074x

Vicore Pharma Holding AB (publ) cash flow conversion efficiency. Based on the latest financial reports, Vicore Pharma Holding AB (publ) (VICO) has a cash flow conversion efficiency ratio of -0.074x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-81.48 Million ≈ $-8.77 Million USD) by net assets (Skr1.10 Billion ≈ $117.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Vicore Pharma Holding AB (publ) (2012–2025)

Cash flow conversion efficiency of Vicore Pharma Holding AB (publ) from 2012 to 2025. This chart illustrates how Vicore Pharma Holding AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View VICO stock price and chart for real-time trading data and today's change.

Vicore Pharma Holding AB (publ) Cash Flow Conversion Ratio Explained

Vicore Pharma Holding AB (publ) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Vicore Pharma Holding AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vicore Pharma Holding AB (publ) ranked by their cash flow conversion efficiency. Also see market cap of Vicore Pharma Holding AB (publ) for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
New Best Wire Industrial Co Ltd TWO:5013	0.007x
Marine Products Corporation NYSE:MPX	0.077x
Shenwu Energy Saving Co Ltd SHE:000820	-0.017x
Dah San Electric Wire & Cable Co Ltd TW:1615	0.047x
Embecta Corp NASDAQ:EMBC	-0.068x
Rubellite Energy Inc TO:RBY	0.090x
Cosmos Group Co Ltd SHE:002133	0.042x
Sysage Technology Co Ltd TW:6112	-0.054x

Annual Cash Flow Conversion Efficiency for Vicore Pharma Holding AB (publ) (2012–2025)

The table below shows the annual cash flow conversion efficiency of Vicore Pharma Holding AB (publ) from 2012 to 2025. Review how much free cash does Vicore Pharma Holding AB (publ) generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr1.10 Billion ≈ $117.89 Million	Skr-374.44 Million ≈ $-40.30 Million	-0.342x	-134.02%
2024-12-31	Skr1.13 Billion ≈ $121.53 Million	Skr-164.95 Million ≈ $-17.75 Million	-0.146x	+73.35%
2023-12-31	Skr455.39 Million ≈ $49.01 Million	Skr-249.58 Million ≈ $-26.86 Million	-0.548x	+47.17%
2022-12-31	Skr289.08 Million ≈ $31.11 Million	Skr-299.92 Million ≈ $-32.28 Million	-1.037x	-49.97%
2021-12-31	Skr383.32 Million ≈ $41.25 Million	Skr-265.17 Million ≈ $-28.54 Million	-0.692x	-104.48%
2020-12-31	Skr354.51 Million ≈ $38.15 Million	Skr-119.94 Million ≈ $-12.91 Million	-0.338x	-25.06%
2019-12-31	Skr321.60 Million ≈ $34.61 Million	Skr-87.00 Million ≈ $-9.36 Million	-0.271x	-133.73%
2018-12-31	Skr285.44 Million ≈ $30.72 Million	Skr-33.04 Million ≈ $-3.56 Million	-0.116x	-69.69%
2017-12-31	Skr112.97 Million ≈ $12.16 Million	Skr-7.71 Million ≈ $-829.18K	-0.068x	+28.89%
2016-12-31	Skr75.60 Million ≈ $8.14 Million	Skr-7.25 Million ≈ $-780.32K	-0.096x	-113.43%
2015-12-31	Skr81.93 Million ≈ $8.82 Million	Skr-3.68 Million ≈ $-396.24K	-0.045x	+14.58%
2014-12-31	Skr53.70 Million ≈ $5.78 Million	Skr-2.83 Million ≈ $-304.02K	-0.053x	-17.40%
2013-12-31	Skr40.01 Million ≈ $4.31 Million	Skr-1.79 Million ≈ $-192.96K	-0.045x	+29.52%
2012-12-31	Skr26.25K ≈ $2.82K	Skr-1.67K ≈ $-179.61	-0.064x	--

About Vicore Pharma Holding AB (publ)

ST:VICO Sweden Biotechnology

Market Cap

$279.94 Million

Skr2.60 Billion SEK

Market Cap Rank

#14856 Global

#244 in Sweden

Share Price

Skr9.24

Change (1 day)

-2.74%

52-Week Range

Skr8.70 - Skr15.68

All Time High

Skr37.60